About this trial

Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).

Eligibility criteria

Qualifiers

Patients affiliated with, or beneficiaries of, a social security scheme.

Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).

Disqualifiers

Patients under 18 years of age.

Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

3
French Guiana
Centre Hospitalier Universitaire de la Guyane97306, Cayenne French Guiana
Guadeloupe
CHU de la Guadeloupe97159, Pointe-à-Pitre Guadeloupe
Reunion
Centre Hospitalier Universitaire de la Réunion97400, Saint-Denis Reunion

Sponsors and collaborators

Centre Hospitalier Universitaire de la Guadeloupe

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Collaborator